AI Article Synopsis
- Tumor necrosis factor inhibitors (TNFi) like infliximab (IFX) are effective treatments for Ankylosing Spondylitis (AS), but there are limited studies on their effects specifically in the Japanese population.
- A study evaluated 11 AS patients treated with IFX, finding significant improvements in disease activity (BASDAI score) and inflammation markers (CRP levels) after an average of 19 months.
- The findings suggest that IFX is both effective and safe for treating AS in Japanese patients, with no serious side effects reported.
Article Abstract
Purpose: Tumor necrosis factor inhibitors (TNFi) such as infliximab (IFX) and adalimumab have been shown to be efficacious not only for rheumatoid arthritis but also for Ankylosing Spondylitis (AS). However, only a limited number of reports regarding the effect of TNFi on AS in Japanese population have been published.
Materials And Methods: We retrospectively evaluated all 11 patients (8 males and 3 females) with AS who were treated with IFX.
Results: After a mean follow-up period of 19 months, the mean BASDAI decreased from 4.7 ± 2.2 to 1.7 ± 1.2 and the serum CRP level decreased from 1.62 ± 1.94 mg/dl to 0.23 ± 0.45 mg/dl. There was no case of serious infection or anaphylaxis.
Conclusions: Our results indicate that IFX is efficacious and safe for AS in Japanese patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!